The rare disease CTLA-4 insufficiency causes regulatory T cells to function abnormally and leads to severe autoimmunity. It also means patients can struggle to fight off recurring infections by the same viruses and bacteria as their immune system "memory" is broken. Sometimes CTLA-4 insufficiency leads to lymphoma.

Using the CRISPR-Cas9 system, the researchers targeted the gene mutation in T cells taken from patients with CTLA-4 insufficiency and repaired the errors (Science Translational Medicine, October 26, 2022). The levels of CTLA-4 in the cells were restored to the levels seen in healthy T cells. Injecting the gene-edited T cells into mice also improved symptoms caused by CTLA-4 insufficiency.

The technique keeps the endogenous mechanisms controlling gene expression intact, while at the same time correcting the mistake in the gene itself. While the technique was used for CTLA-4 insufficiency, the gene-editing strategy could be adapted for other conditions, according to the researchers.

Applied DNA and EvviVax publish data for potential cancer immunotherapy
Applied DNA Sciences and EvviVax have published a manuscript detailing a preclinical study showing that LinearDNA vaccines used for cancer immunotherapy...

Harbour BioMed successfully doses antiCTLA-4 antibody
Harbour BioMed has successfully completed dosing of the first patient in a phase IB/IIA trial at the stage of dose expansion of its anticytotoxic T-lymphocyte-associated...

What makes immunotherapies successful in one tumor but not in others?
Researchers have developed a new framework to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies. The...

AACR 2021: A case study of T-cell modulation for cancer immunotherapies
During a plenary session at the American Association for Cancer Research (AACR) 2021 virtual meeting held April 9-14, speakers described impressive work...